Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.

@article{Liu2016IrinotecanDB,
  title={Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.},
  author={Xiangsheng Liu and Allen Situ and Yanan Kang and Katie Rose Villabroza and Yu-Pei Liao and Chong Hyun Chang and Timothy R. Donahue and Andre E. Nel and Huan Meng},
  journal={ACS nano},
  year={2016},
  volume={10 2},
  pages={
          2702-15
        }
}
Urgent intervention is required to improve the 5 year survival rate of pancreatic ductal adenocarcinoma (PDAC). While the four-drug regimen, FOLFIRINOX (comprising irinotecan, 5-fluorouracil, oxaliplatin, and leucovorin), has a better survival outcome than the more frequently used gemcitabine, the former treatment platform is highly toxic and restricted for use in patients with good performance status. Since irinotecan contributes significantly to FOLFIRINOX toxicity (bone marrow and… 

Figures from this paper

Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview

TLDR
It is concluded that MSN-based tumor-targeting strategies may indeed hold therapeutic potential for PDAC, although true clinical translation has lagged behind.

ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer

TLDR
A novel ADAM9-responsive, protease-dependent, drug delivery system for PDAC as a promising tool to reduce the cytotoxicity of systemic chemotherapy is introduced.

Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer.

TLDR
Improved drug delivery was accompanied by substantially improved efficacy, increased survival, and reduced bone marrow and GI toxicity compared to the free drug and Onivyde, and the Ir-silicasome appears to be promising as a treatment option for CRC in humans based on improved efficacy and the carrier's favorable safety profile.

Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer

TLDR
It is demonstrated that iRGD enhances the efficacy of irinotecan-loaded silicasome–based therapy and may be a suitable adjuvant in nanoparticle-based treatments for PDAC.

Efficient nano-enabled therapy for gastrointestinal cancer using silicasome delivery technology

TLDR
Progress in the development of a series of rationally designed mesoporous silica nanoparticles (MSNP), which includes the use of a supported lipid bilayer, is reviewed to provide more efficacious and well-tolerated chemotherapy and/or chemo-immunotherapy for the different types of gastrointestinal (GIT) cancer.

Dacarbazine-Loaded Hollow Mesoporous Silica Nanoparticles Grafted with Folic Acid for Enhancing Antimetastatic Melanoma Response.

TLDR
In vivo investigations demonstrate that the rationally designed nanocarrier loaded with DTIC achieves significant improvement against lung metastasis of melanoma via targeting melanoma cells and tumor-associated macrophages.

Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic Outcome in Pancreatic Cancer.

TLDR
A rationally designed mesoporous silica nanoparticle (MSN)-based platform is reported for the target-specific, spatiotemporal, ratiometric, and safe co-delivery of Gem and cisplatin (cisPt) and shows that systemic administration of the nanoparticles results in synergistic therapeutic outcome.

Noninvasive Preclinical Evaluation of Targeted Nanoparticles for the Delivery of Curcumin in Treating Pancreatic Cancer.

TLDR
It is proposed that transferrin targeted, PEGylated, mesoporous silica nanoparticles can be used as a carrier to deliver curcumin, and used in addition to gemcitabine to reduce disease burden significantly for pancreatic cancer patients.

Targeted drug delivery using iRGD peptide for solid cancer treatment.

TLDR
This focused review summarized the design and implementation strategy for iRGD-mediated tumor targeting, including the working principle of such peptide and discussion on patient-specific iR GD effect in vivo, commensurate with the level of key biomarker expression on tumor vasculature.
...

References

SHOWING 1-10 OF 79 REFERENCES

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

TLDR
This study shows that intraliposomal stabilization of CPT-11 using a polymeric or highly charged, nonpolymeric polyanionic trapping agent results in a markedly active antitumor agent with low toxicity.

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

TLDR
PEP02 demonstrates moderate antitumour activity with a manageable side effect profile for metastatic, gemcitabine-refractory pancreatic cancer patients, and a phase 3 trial of PEP02 (MM-398), known as NAPOLI-1, is currently underway.

Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

TLDR
Proof-of-principle testing of the use of a dual drug/siRNA nanocarrier to overcome Dox resistance in a xenograft is provided and the first detailed analysis of the impact of heterogeneity in the tumor microenvironment on the efficacy of siRNA delivery in vivo is provided.

Liposomal Irinotecan

TLDR
Low-performance liquid chromatographic analysis of plasma samples indicated that liposomal irinotecan was protected from inactivating hydrolysis to the carboxylate form, and this formulation exhibited substantially improved therapeutic effects.

Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.

TLDR
The strategy of coencapsulating both I&C in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer.

Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves.

TLDR
A novel MSNP delivery system capable of drug delivery based on the function of beta-cyclodextrin (beta-CD) nanovalves that are responsive to the endosomal acidification conditions in human differentiated myeloid and squamous carcinoma cell lines are reported.

Development of High-Content Gemcitabine PEGylated Liposomes and Their Cytotoxicity on Drug-Resistant Pancreatic Tumour Cells

TLDR
Remote loading was not suitable for loading gemcitabine into liposomes, and minimal drug leakage, good stability, and significant improvement in cytotoxicity to the gem citabine-resistant pancreatic cancer cell lines were observed.

Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using a Fucose-Bound Nanoparticle Approach

TLDR
Intravenously injected L-fucose-bound liposomes carrying Cisplatin were successfully delivered to pancreatic cancer cells, mediating efficient tumor growth inhibition as well as prolonging survival in mouse xenograft models, indicating this modality represents a new strategy for pancreatic cancers cell-targeting therapy.

Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals.

TLDR
The results indicate that MSNs are biocompatible, preferentially accumulate in tumors, and effectively deliver drugs to the tumors and suppress tumor growth.
...